Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07427563

Cerebellar Deep Brain Stimulation for the Treatment of Ataxia

Cerebellar Deep Brain Stimulation for the Treatment of Refractory Ataxia and Gait Disorders: Pilot Trial

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
12 (estimated)
Sponsor
University Health Network, Toronto · Academic / Other
Sex
All
Age
20 Years – 70 Years
Healthy volunteers
Not accepted

Summary

Abnormal gait is often associated with immobility and falls, which in turn lead to loss of functional independence and death. While gait disorders may arise from many different etiologies, dysfunction of the cerebellum (a part of the brain with the function of coordination of movement) leading to gait disorders results in distinct features. Gait ataxia is a specific type of neurological gait disorder and is defined as the presence of abnormal, uncoordinated movements associated with gait. To date, there are limited treatments for ataxia and/or gait disorders. Deep brain stimulation (DBS) is a neurosurgical tool that has been widely used for over twenty years, mainly to treat Parkinson's disease, dystonia, and essential tremor. In this study, we aim to implant DBS in patients with ataxia and/or gait disorder in the cerebellum area, and electrically stimulate them in a titratable and ultimately reversible manner. This study is divided into 3 phases: pre-operative, operative and post-operative phase. The purpose of this pilot study is to evaluate the safety, feasibility, and to validate the DBS of cerebellar cortical and deep nuclei in patients with treatment refractory ataxia. Twelve(12 ) patients will be enrolled in this study.

Conditions

Interventions

TypeNameDescription
DEVICEDeep Brain StimulationStandard of care Neurosugical implantation of Deep Brain Stimulation under general anesthesia

Timeline

Start date
2023-03-02
Primary completion
2030-12-31
Completion
2035-12-31
First posted
2026-02-23
Last updated
2026-02-23

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT07427563. Inclusion in this directory is not an endorsement.